Micell Technologies^® is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. By applying unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of bioabsorbable polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-eluting balloon for vascular interventions.

The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on resolving known problems with current durable polymer-based drug-eluting technologies. The company's lead product candidate, MiStent^® Sirolimus Eluting Absorbable Polymer Coronary Stent System ("MiStent^® SES") is in the clinical stage of development and is being studied to merge the therapeutic efficacy potential of a sirolimus-eluting stent with the long-term safety characteristics of a bare-metal stent.